Tags

Type your tag names separated by a space and hit enter

Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
Expert Opin Investig Drugs. 2012 Sep; 21(9):1267-308.EO

Abstract

INTRODUCTION

According to the definition of the Committee to Identify Neuroprotective Agents in Parkinson's Disease (CINAPS), "neuroprotection would be any intervention that favourably influences the disease process or underlying pathogenesis to produce enduring benefits for patients" [Meissner W, et al. Trends Pharmacol Sci 2004;25:249-253]. Preferably, neuroprotective agents should be used before or eventually during the prodromal phase of the diseases that could start decades before the appearance of symptoms. Although several symptomatic drugs are available, a disease-modifying agent is still elusive.

AREAS COVERED

The aim of the present review is to give an overview of neuroprotective agents being currently investigated for the treatment of AD, PD, HD and ALS in clinical phases.

EXPERT OPINION

Development of effective neuroprotective therapies resulting in clinically meaningful results is hampered by several factors in all research stages, both conceptual and methodological. Novel solutions might be offered by evaluation of new targets throughout clinical studies, therapies emerging from drug repositioning approaches, multi-target approaches and network pharmacology.

Links

Publisher Full Text

Authors+Show Affiliations

Dunkel P
Semmelweis University, Department of Organic Chemistry, Budapest, Hungary.
Chai CL
No affiliation info available
Sperlágh B
No affiliation info available
Huleatt PB
No affiliation info available
Mátyus P
No affiliation info available

MeSH

Alzheimer DiseaseAmyotrophic Lateral SclerosisAnimalsDrug DesignHumansHuntington DiseaseNeurodegenerative DiseasesNeuroprotective AgentsParkinson Disease

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

22741814

Citation

Dunkel, Petra, et al. "Clinical Utility of Neuroprotective Agents in Neurodegenerative Diseases: Current Status of Drug Development for Alzheimer's, Parkinson's and Huntington's Diseases, and Amyotrophic Lateral Sclerosis." Expert Opinion On Investigational Drugs, vol. 21, no. 9, 2012, pp. 1267-308.
Dunkel P, Chai CL, Sperlágh B, et al. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. Expert Opin Investig Drugs. 2012;21(9):1267-308.
Dunkel, P., Chai, C. L., Sperlágh, B., Huleatt, P. B., & Mátyus, P. (2012). Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. Expert Opinion On Investigational Drugs, 21(9), 1267-308. https://doi.org/10.1517/13543784.2012.703178
Dunkel P, et al. Clinical Utility of Neuroprotective Agents in Neurodegenerative Diseases: Current Status of Drug Development for Alzheimer's, Parkinson's and Huntington's Diseases, and Amyotrophic Lateral Sclerosis. Expert Opin Investig Drugs. 2012;21(9):1267-308. PubMed PMID: 22741814.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. AU - Dunkel,Petra, AU - Chai,Christina Ll, AU - Sperlágh,Beáta, AU - Huleatt,Paul B, AU - Mátyus,Péter, Y1 - 2012/06/28/ PY - 2012/6/30/entrez PY - 2012/6/30/pubmed PY - 2013/1/5/medline SP - 1267 EP - 308 JF - Expert opinion on investigational drugs JO - Expert Opin Investig Drugs VL - 21 IS - 9 N2 - INTRODUCTION: According to the definition of the Committee to Identify Neuroprotective Agents in Parkinson's Disease (CINAPS), "neuroprotection would be any intervention that favourably influences the disease process or underlying pathogenesis to produce enduring benefits for patients" [Meissner W, et al. Trends Pharmacol Sci 2004;25:249-253]. Preferably, neuroprotective agents should be used before or eventually during the prodromal phase of the diseases that could start decades before the appearance of symptoms. Although several symptomatic drugs are available, a disease-modifying agent is still elusive. AREAS COVERED: The aim of the present review is to give an overview of neuroprotective agents being currently investigated for the treatment of AD, PD, HD and ALS in clinical phases. EXPERT OPINION: Development of effective neuroprotective therapies resulting in clinically meaningful results is hampered by several factors in all research stages, both conceptual and methodological. Novel solutions might be offered by evaluation of new targets throughout clinical studies, therapies emerging from drug repositioning approaches, multi-target approaches and network pharmacology. SN - 1744-7658 UR - https://www.unboundmedicine.com/medline/citation/22741814/Clinical_utility_of_neuroprotective_agents_in_neurodegenerative_diseases:_current_status_of_drug_development_for_Alzheimer's_Parkinson's_and_Huntington's_diseases_and_amyotrophic_lateral_sclerosis_ L2 - http://www.tandfonline.com/doi/full/10.1517/13543784.2012.703178 DB - PRIME DP - Unbound Medicine ER -